Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

AAPS Journal

Volumn 18, Issue 5, 2016, Pages 1192-1202

  Jones, Aksana K ^a   Freise, Kevin J ^a   Agarwal, Suresh K ^a   Humerickhouse, Rod A ^a   Wong, Shekman L ^a   Salem, Ahmed Hamed ^a,b  

^a ABBVIE INC   (United States)

^b Ain Shams University   (Egypt)

Author keywords

CYP3A interactions; food effect; population pharmacokinetics; renal and hepatic impairment; rituximab; venetoclax

Indexed keywords

ANTINEOPLASTIC AGENT; FAT INTAKE; FUSED HETEROCYCLIC RINGS; SULFONAMIDE; VENETOCLAX;

ADMINISTRATION AND DOSAGE; ADULT; AGED; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; FAT INTAKE; FEMALE; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; COHORT STUDIES; DIETARY FATS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SULFONAMIDES;

EID: 84970971332     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-9927-9     Document Type: Article

References (40)

1. Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013;88:803–16.
2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052–7. Erratum in: N Engl J Med. 333;1515.
3. Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011;11:1379–90.
4. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998;25:42–59.
5. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.
6. Kitada S, Pedersen IM, Schimmer AD, Reed JC. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene. 2002;21:3459–74.
7. Zaja F, Di Loreto C, Amoroso V, Salmaso F, Russo D, Silvestri F, et al. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. Leuk Lymphoma. 1998;28:567–72.
8. Tomek M, Akiyama T, Dass CR. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J Pharm Pharmacol. 2012;64:1695–702.
9. Owen C, Assouline S, Kuruvilla J, Uchida C, Bellingham C, Sehn L. Novel therapies for chronic lymphocytic leukemia: a Canadian perspective. Clin Lymphoma Myeloma Leuk. 2015;15:627–34.
10. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.
11. Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K, et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol Res Perspect. 2015;3, e00178.
12. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–22.
13. Gerecitano JF, Roberts AW, Seymour JF, Wierda WG, Kahl BS, Pagel JM, et al. A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126:254.
14. Ma S, Brander DM, Seymour JF, Kipps TJ, Barrientos JC, Davids MS, et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood. 2015;126:830.
15. Konopleva M, Pollyea D, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase 2 study of venetoclax monotherapy in patients with acute myelogenous leukaemia. Cancer Discov. 2016, submitted.
16. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results. Blood. 2015;126:3038.
17. DiNardo C, Pollyea D, Pratz K, Thirman MJ, Letai A, Frattini M, et al. A Phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126:327.
18. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guide part V. 2013. https://nonmem.iconplc.com/nonmem730/Latest_User…/guides/V.pdf. Accessed 22 Feb 2016.
19. United States Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. 2010. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM204959.pdf. Accessed 22 Feb 2015.
20. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol. 2010;28:4507–12.
21. Ferri FF. Ferri’s best test: a practical guide to laboratory medicine and diagnostic imaging. 3rd ed. Philadelphia: Saunders, an imprint of Elsevier Inc.; 2015.
22. Vogel HG, Maas J, Gebauer A. Drug discovery and evaluation: methods in clinical pharmacology. Berlin: Springer; 2011.
23. University of Washington. Drug interaction database program. https://www.druginteractioninfo.org/. Accessed 22 Feb 2016.
24. United States Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 22 Feb 2015.
25. University of California, San Francisco. UCSF-FDA transportal. http://dbts.ucsf.edu/fdatransportal/index/. Accessed 22 Feb 2016.
26. Indiana University Department of Medicine. P450 drug interaction table. http://medicine.iupui.edu/clinpharm/ddis/main-table/. Accessed 22 Feb 2016.
27. Pharmacology Weekly. Online drug therapy tables. https://archive.is/ULoJ4. Accessed 22 Feb 2016.
28. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693–705.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
30. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.
31. Yanez JA, Remsberg CM, Sayre CL, Forrest ML, Neal M. Flip-flop pharmacokinetics—delivering a reversal of disposition: challenges and opportunities during drug development: challenges and opportunities during drug development. Ther Deliv. 2011;2:643–72.
32. Duffull SB, Wright DFB, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses—a clinical viewpoint. Br J Clin Pharmacol. 2011;71:807–14.
33. Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14:119–32.
34. Ludden TM. Nonlinear pharmacokinetics. Clin Pharmacokinet. 1991;20:429–46.
35. Lee PID, Amidon GL. Pharmacokinetic analysis: a practical approach. Lancaster: Technomic Publishing Company, Inc.; 1996.
36. Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016. doi:10.1002/jcph.741.
37. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. 2016. doi:10.1002/jcph.730.
38. Agarwal S, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M., et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor, in patients with Non-Hodgkin lymphoma. Br J Clin Pharmacol. 2016, submitted.
39. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275–83.
40. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74:275–87.